For information, since interpretation of data from the EMPACT-MI trial is ongoing, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Further updates will be communicated when available. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6240

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
24 May 2024 Suspended. For information, since interpretation of data from the EMPACT-MI trial is ongoing, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Further updates will be communicated when available. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
04 March 2024 - 03 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6240
04 March 2024 In progress. Scoping commenced.
31 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual